Paradigm Biocapital Advisors LP Crinetics Pharmaceuticals, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.14 Billion
- Q2 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,343,553 shares of CRNX stock, worth $99.2 Million. This represents 3.15% of its overall portfolio holdings.
Number of Shares
2,343,553
Previous 1,946,168
20.42%
Holding current value
$99.2 Million
Previous $65.3 Million
3.26%
% of portfolio
3.15%
Previous 3.34%
Shares
12 transactions
Others Institutions Holding CRNX
# of Institutions
237Shares Held
90.2MCall Options Held
59.7KPut Options Held
14.8K-
Vanguard Group Inc Valley Forge, PA9.26MShares$392 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.4MShares$271 Million1.78% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$264 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA5.81MShares$246 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.59MShares$237 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.27B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...